Robbie Huang, n/a

Executive Scientific Director
Xeris Pharmaceuticals
Chicago, Illinois, United States

Disclosure information not submitted.

Presentation(s):

• MON-390 - XP-8121: Once-Weekly Subcutaneous Levothyroxine Bypassing GI Interactions and Reduced Dose Requirements - Insights from A Phase 2 Study

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT